Environmental air monitoring in international airports: A novel approach for enhanced pathogen surveillance

Dawn Gratalo[1], Cindy R. Friedman*[2], Valerie J. Morley[1], Xueting Qiu[1,4], Ian Ruskey[2], Andrew P. Rothstein[1], Patrick B. Tiburcio[3], Casandra W. Philipson[1,4], Thomas W.S. Aichele[1,4], Stephen M. Bart[2,4], Dustin Jaynes[5], Birgitte B. Simen[1] , Shelby L O'Connor[3], David H. O'Connor*[3]

[1] Ginkgo Biosecurity, 27 Drydock Ave 8th Floor, Boston, MA, USA

[2] Division of Global Migration Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

[3] Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI USA

[4] Former Affiliation

[5] Department of Public Safety, Dallas/Fort Worth International Airport, Texas, USA

Corresponding authors email: ccf6@cdc.gov and dhoconno@wisc.edu

Abstract

Early detection of outbreaks and emerging pathogens is critical for public health and global biosecurity. Airports, as major international travel hubs with dense, enclosed populations, are high-risk settings for disease transmission and potential pathogen introduction. The U.S. Centers for Disease Control and Prevention, in collaboration with Ginkgo Biosecurity and the University of Wisconsin–Madison, implemented air monitoring for pathogen surveillance in congregate areas at four U.S. international airports. From October 2023 to August 2024, SARS-CoV-2 was detected by PCR in 98.3% of air samples and influenza A in 17.2%. These results correlated with

positivity trends from other sample modalities, including aviation wastewater, traveler nasal swabs, and national clinical surveillance data. Targeted amplicon sequencing of SARS-CoV-2 from air samples correlated with contemporaneous lineages in wastewater collected and sequenced from the same airports. Metagenomic enrichment sequencing detected 30 viral species and recovered high-quality genomes for SARS-CoV-2, influenza, bocavirus, and seasonal coronaviruses. Together, these findings demonstrate that air sampling is a complementary surveillance modality to aviation wastewater for early pathogen detection at ports of entry.

Key Words: Air monitoring, pathogen surveillance, airports, wastewater, SARS-CoV-2, influenza, metagenomic sequencing, environmental surveillance, pandemic preparedness, biosecurity

Introduction

Epidemic and pandemic preparedness relies heavily on robust and adaptive surveillance systems capable of early pathogen detection. Global travel hubs, particularly international airports, are critical interfaces for the introduction and spread of emerging and re-emerging pathogens due to their dense, transient populations and high interconnectedness.[1–4] Detecting pathogens and identifying new variants in airports is especially important, as illustrated during the COVID-19 pandemic, which underscored the urgent need for near real-time genomic surveillance strategies.[5] While testing of nasal swabs from arriving travelers provides one modality for monitoring, the process can be labor-intensive and relies on traveler willingness to participate.

Environmental surveillance has emerged as a non-invasive approach to characterize pathogens circulating in communities. Wastewater surveillance, including community and aviation wastewater, has demonstrated utility in tracking both the prevalence and genetic diversity of

48 viruses such as SARS-CoV-2.[6–8] Air monitoring serves as a complementary public health
49 surveillance tool, enabling the collection of pathogenic genetic material shed by individuals. This
50 approach is particularly effective for capturing respiratory pathogens from diverse populations,
51 including asymptomatic or pre-symptomatic individuals who might not otherwise engage with
52 clinical testing or contribute to accessible wastewater systems. Studies have shown the
53 effectiveness of air sampling in multiple congregate settings. In hospitals, airborne pathogen
54 detection has correlated strongly with clinical data [9], and airborne pathogen genetic material has
55 also been detected in other communal spaces such as schools.[10–12] As a scalable and cost-
56 effective surveillance option, non-invasive air monitoring is particularly relevant for high-traffic
57 environments, such as international airports, that serve as gateways into communities.

58 While PCR-based detection confirms the presence of pathogen genetic material, genomic
59 sequencing is essential for identifying specific lineages, tracking variant evolution, and
60 informing the development of diagnostics and therapeutics.[13–16] However, obtaining high-quality
61 genomic data from air samples presents challenges due to low biomass and nucleic acid
62 degradation, especially for RNA viruses.[17] Advanced sequencing methodologies are therefore
63 crucial. Targeted amplicon sequencing offers high sensitivity but is limited to a narrow range of
64 pathogens, while metagenomic approaches provide an agnostic view but often lack sensitivity for
65 low-abundance targets. Metagenomic enrichment sequencing represents a promising strategy to
66 improve both breadth and sensitivity by enriching viral nucleic acids prior to sequencing.[9,18]

67 In this study, air monitoring surveillance was implemented in congregate areas of four major
68 U.S. international airports to assess the feasibility of detection of SARS-CoV-2 and Influenza A
69 virus genetic material in an international airport setting; evaluate the effectiveness of sequencing
70 methods for viral genome characterization from these air samples; and determine the

complementary value of air monitoring within existing pathogen surveillance frameworks. This study explores the development of air monitoring as a proactive biosecurity system, to enhance our capacity for early threat identification at the critical intersection of global travel and community health.

Methods

ThermoFisher AerosolSense™ active air samplers were placed in congregate areas adjacent to customs and immigration inspection areas and within proximity of several hundred arriving international passengers at San Francisco International Airport, California (SFO); Newark Liberty International Airport, New Jersey (EWR); Washington Dulles International Airport, Virginia (IAD); and Dallas/Fort Worth International Airport, Texas (DFW). Samplers were placed on tables 28-30 inches above the ground. The ThermoFisher AerosolSense™ has a built-in pump, that operates at 200 liters per minute, and a proprietary sample collection cartridge. Each ThermoFisher AerosolSense™ unit collected samples for 10 hours per day**.** ThermoFisher AerosolSense™ cartridges containing polyurethane foam substrates were removed from each air sampling machine after approximately 20 hours of use Monday through Thursday and after 30 hours of use Friday through Sunday.

Samples were collected from October 18, 2023–August 27, 2024, at SFO, EWR, and IAD, and from February 7–August 14, 2024, at DFW. At SFO, a second sampler was added on June 3, 2024 (denoted by the orange star in Figure 1), and both instruments operated until study end. Cartridges were packaged and shipped at room temperature to UW-Madison for extraction and qRT-PCR analyses. All results were linked to airport and collection date via unique barcodes. Each substrate was submerged in 500 µL of 1X phosphate-buffered saline (PBS) and vortexed.

93 RNA was extracted from 300 µL of eluate using a Maxwell® RSC Viral Total Nucleic Acid
94 Purification Kit (Promega). Molecular detection of SARS-CoV-2, influenza A, and RNase P is
95 described in Supplemental Methods. From October 18, 2023–March 12, 2024, qRT-PCR
96 reactions were performed on a LightCycler® 480 System (Roche) using a TaqMan Fast Virus 1-
97 Step Kit (ThermoFisher) with CDC-modified assays targeting the SARS-CoV-2 nucleocapsid
98 gene (N1, N2) and the influenza A M gene, in duplicate.[19] Pathogen results were categorized as
99 positive if both Ct values were <40, inconclusive if only one Ct <40, and negative if neither Ct
100 <40**.** This categorization applied to both SARS-CoV-2 and influenza A assays. On March 12,
101 2024, the thermocycler was changed to accommodate a multiplex assay (denoted by the red star
102 in Figure 1). For each cartridge, a single multiplex assay measuring the SARS-CoV-2 N1 and
103 influenza A M targets were performed. The human RNase P gene served as an internal control;
104 samples negative for RNase P were excluded from analysis.

105 For targeted SARS-CoV-2 sequencing, purified total nucleic acid (TNA) was amplified by
106 multiplex RT-PCR (NEB LunaScript Multiplex One-Step RT-PCR) using the ARTIC primer set
107 (IDT ARTIC V5.3.2 NCOV-2019 Panel).[20] Amplicons were pooled, and libraries prepared with
108 a modified Illumina DNA Prep protocol. Libraries were sequenced on an Illumina NovaSeq
109 6000, targeting ~1.5 million paired-end 150 bp reads per sample.

110 For metagenomic enrichment sequencing, input to library prep was either total nucleic acid
111 (TNA) or clean and concentrated TNA (Zymo Research, Irvine, CA). Extracts were prepared for
112 enrichment using the Illumina RNA for Enrichment Sample Preparation Kit with the Respiratory
113 Virus Oligo Panel, following the manufacturer's protocol (Illumina, San Diego, CA). Libraries
114 were validated for size and adapter dimer removal on an Agilent TapeStation 4200 D1000 High
115 Sensitivity assay, quantified and normalized using the dsDNA High Sensitivity Assay on a Qubit

116 3.0 (Life Technologies, Carlsbad, CA), denatured/diluted, and pooled per manufacturer's
117 instructions. Pooled libraries were sequenced on the Illumina NovaSeq 6000 (v1.5 chemistry) to
118 a target depth of ~7 million paired-end 150 bp reads per sample. Bioinformatics pipelines and
119 analysis details are provided in Supplemental Data.

120 For aviation wastewater and traveler nasal swabs, data were generated from samples collected
121 and processed as part of the Traveler Genomic Surveillance (TGS) program from October 18th,
122 2023-August 27th, 2024. Aviation wastewater was collected from arriving international airplanes
123 at IAD (N=330), and SFO wastewater was collected from triturators (N=161).Triturators are
124 **c**ollection points where waste from multiple flights is discharged and homogenized before being
125 combined with airport terminal wastewater. Travelers volunteered to self-collect anterior nasal
126 swabs on arrival at IAD (N = 16,004) and SFO (N = 30,182). Wastewater samples were
127 concentrated with Nanotrap Microbiome Particles and extracted using a MagMAX Microbiome
128 Ultra Nucleic Acid Isolation Kit (Thermo Fisher). Extracts were tested by digital PCR for SARS-
129 CoV-2 and influenza A/B (Qiagen), and SARS-CoV-2 sequencing was performed as described
130 above.

131 Upon laboratory receipt, nasal swab samples were heat-inactivated at 70°C for 30 minutes, and
132 total nucleic acids extracted using the MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit
133 (Thermo Fisher). Extracts were tested by qPCR using the TrueMark™ SARS-CoV-2/Flu A/Flu
134 B/RSV Select Panel on a QuantStudio™ 5 qPCR instrument (Thermo Fisher). SARS-CoV-2
135 sequencing was performed as described above.

136 This activity was reviewed by CDC, deemed not human subjects research, and conducted in
137 accordance with applicable federal law and CDC policy (45 CFR part 46; 21 CFR part 56).

138 **Results**

139 During October 18, 2023–August 27, 2024, 463 air monitoring samples were collected and tested
140 by qRT-PCR from four international airports (Figure 1). The RNase P control was positive for
141 460 of 463 samples (99.1%). Among these 460 RNAseP+ samples, SARS-CoV-2 was detected
142 in 452 (98.3%). Of the remaining eight samples, five were negative and three were inconclusive.
143 When stratified by airport, positive SARS-CoV-2 detections were: SFO: 137 (97.9%), EWR: 124
144 (98.4%), IAD: 118 (97.5%), and DFW: 73 (100%) (Figure 1).

145 Among the 460 RNAseP+ samples, 79 were positive for influenza A (17.2%), while 327 were
146 negative and 54 were inconclusive. By airport, influenza A detections were: SFO: 36 (25.7%),
147 EWR: 20 (15.9%), IAD: 10 (8.3%), and DFW: 13 (17.8%). Positive detections of influenza A
148 occurred weekly between January 1 and March 18, 2024, then occurred sporadically through
149 April 22, 2024, after which no further positives were observed (Figure 1).

150 To compare SARS-CoV-2 and influenza A trends across modalities, data from two airports (SFO
151 and IAD) with overlapping aviation wastewater, airport air, and traveler nasal swab collections
152 were analyzed. Publicly available U.S. clinical respiratory specimen data
153 (https://www.cdc.gov/nrevss/php/dashboard/index.html) were also included for comparison.
154 Airport air and aviation wastewater had higher weekly positivity rates for SARS-CoV-2 and
155 influenza A than traveler nasal swabs and national clinical samples, reflecting expected
156 differences between population-level (air, wastewater) and individual-level (nasal swab)
157 sampling (Figure 2A). SARS-CoV-2 PCR values from air sampling correlated significantly with
158 aviation wastewater (Figure 2B; Pearson's $p < 0.001$), but not with percent positivity in traveler
159 nasal swabs (Figure 2C; $p = 0.24$), and national surveillance (Figure 2D; $p = 0.13$). Influenza A

160 positivity from air sampling correlated significantly with aviation wastewater (Figure 2E; $p =$
161 0.002), traveler nasal swabs (Figure 2F; $p < 0.001$), and national surveillance (Figure 2G; $p <$
162 0.001).

163 Of the 460 RNAseP+ air samples, 338 were tested for SARS-CoV-2 sequences; 216 (64%)
164 yielded high-quality genomes (≥70% genome coverage), and 167 (77%) of those contained
165 multiple lineages including BA.2.86, JN.1, JN.1.16, JN.1.67, KP.1, KP.2, KP.3, KP.3.1.1, and
166 XDV. SARS-CoV-2 variant trends in air and aviation wastewater samples were similar at both
167 airports (Figure 3A, 3B). Between January 29 and August 26, 2024, both sample types showed a
168 decline in Omicron JN.1 and an increase in KP.2/KP.3, consistent with contemporaneous
169 national trends.[21] KP.x variants were detected in aviation wastewater earlier than air samples (42
170 days earlier for KP.2, 41 days earlier for KP.3).

171 Metagenomic sequencing with hybrid capture enrichment for respiratory virus genomes was
172 performed on a total of 98 air samples, split into two sequencing runs (Figure 4), using samples
173 that did not overlap with those used for SARS-CoV-2 amplicon sequencing. In the first run
174 (N=52), a mean of 0.04% (95% CI [0.01%, 0.06%]) of total reads per sample mapped to virus
175 targets. After incorporating a TNA concentration step prior to library prep, the second run (N =
176 46) achieved a mean of 11.8% (95% CI: 7.04 –16.5%) of reads mapping to viral genomes.
177 Across all samples, reads from 30 viral species were detected. The most frequent were SARS-
178 CoV-2 (100% of samples; mean RPKM 1007, 95% CI: 351-1663), influenza A (57% of samples;
179 mean RPKM 111, 95% CI: 62.7-159), and seasonal coronavirus HCoV-229E (45% of samples;
180 mean RPKM 163, 95% CI: 18.9-306). Influenza B (28%), RSV A (29%), and RSV B (43%)
181 were also detected. For influenza A, 88% (28/32) of PCR-positive samples had sequencing reads

182 mapping to the genome. An additional 27 samples with influenza A reads were PCR-
183 inconclusive (n = 12) or negative (n = 15).

184 In addition to revealing viral diversity, enrichment sequencing yielded high-quality genomes
185 (≥70% reference coverage at 10× depth) in 4% (2/52) of samples from the first run and 35%
186 (16/46) of samples from the optimized second run. Overall, 25 high-quality genomes were
187 recovered from 98 samples, including SARS-CoV-2 (n = 11), influenza A (n = 4), bocavirus (n =
188 2), WU polyomavirus (n = 5), and seasonal coronaviruses (n = 3).

189

190 **Discussion**

191 The findings of this project support air sampling as a viable option for pathogen surveillance in
192 airports. The data suggests that i) air sampling can serve as a layered or alternative surveillance
193 option, ii) targeted genomic sequencing from air samples provides the resolution needed to
194 identify important variants, and iii) metagenomic enrichment sequencing enables multipathogen
195 detection from air. To our knowledge, this is the first study to demonstrate a correlation between
196 respiratory viruses detected in air samples, aviation wastewater, and nasal swabs from travelers
197 at the same airport, as well as with national clinical respiratory data. Both air and wastewater
198 monitoring offer valuable insights. The strong correlation in observed trends across these two
199 systems underscores their complementary value in a multi-layered surveillance approach, with
200 each capturing signals from distinct yet overlapping populations.

201 In airport environments, air monitoring offers real-time, surveillance, serving as a crucial
202 interface between emerging threats and community spread. In this project SARS-CoV-2 RNA

203 was detected in nearly all samples (98.3%) compared with 17.2% for influenza A. Influenza A
204 detections were concentrated in the winter months and mirrored national clinical data trends
205 from the 2023-2024 influenza season. The near ubiquitous detection of SARS-CoV-2
206 underscores the value of genomic sequencing for tracking new variant introductions of highly
207 prevalent pathogens. Sequencing in our study showed JN.1 as the predominant lineage, followed
208 by increases in KP.2 and KP.3 sublineages, consistent with national surveillance data.[21] In this
209 study, KP.2 and KP.3 lineages were detected substantially earlier in aviation wastewater than in
210 air samples. However early detection was found to be dependent on the sample type when
211 comparing airplane (IAD) and triturator (SFO) wastewater individually against air samples
212 (Supplemental Fig). While some KP.x signals appeared earlier in air than triturator wastewater at
213 specific time points, a controlled comparison across all modalities at the same airport and time
214 would be required to determine whether this reflects true early detection or variation related to
215 low-abundance airborne material.

216 Genomic sequencing of air sampling has been shown as a highly effective method for pathogen
217 surveillance,[11,12,22]but methodological considerations remain. Targeted amplicon methods,
218 commonly applied to SARS-CoV-2, have excellent sensitivity, which is valuable for identifying
219 circulating lineages, but interrogate only a narrow set of pathogens. Untargeted metagenomic
220 sequencing captures a broader diversity of pathogens; but the low amount of starting genomic
221 material in air samples presents a technical challenge. Here, we addressed this challenge with
222 hybrid-capture enrichment sequencing, enabling detection of a broad panel of pathogens despite
223 the limitations of input material. Our results show that metagenomic enrichment sequencing
224 increased mapped reads and improved recovery of high-quality genomes from air samples. This
225 approach also detected more influenza A material than PCR, though this may reflect limitations

226 of the specific PCR assay (suggested by the number of inconclusive results) as well as the low
227 sequencing thresholds applied in our study (any read counted as detection).

228 Our study identified several limitations. First, variations in viral genome reference coverage, due
229 to differing numbers of reads and depth of coverage, may have impacted lineage assignment,
230 particularly in low-biomass air samples. Second, operational constraints meant sampling duration
231 and cartridge change timing were not fully standardized. However, we believe these modest
232 variations did not materially alter the overall findings. Finally, minor temporal uncertainty in
233 signal attribution may have been introduced by the imprecise placement and removal times of the
234 cartridges.

235 Future research should prioritize enhancing sensitivity by improving air sample collection,
236 nucleic acid recovery, and sequencing efficiency to better detect less abundant pathogens. A
237 parallel focus should be on defining clear detection limits, which will strengthen confidence in
238 genomic data, especially when only limited genomic sequences are recovered.

239 More broadly, air monitoring technologies currently face technical and operational limitations
240 that require further research and development. Before these systems are widely deployed for
241 biosurveillance, their limits of detection, quantification, and optimal sampling time for pathogens
242 of interest must be rigorously characterized under realistic environmental conditions. In addition,
243 a better understanding of how airflow dynamics, building design, and population density
244 influence sampling efficiency and detection probability would substantially enhance the
245 capability and reliability of these technologies.

246 Beyond technical considerations, the operational readiness of air monitoring for routine public
247 health use depends on policy, ethical, and implementation factors. These include data

interpretability for decision-making, coordination with airport authorities and industry partners, governance around data use, and clear triggers for public health response. As with other environmental surveillance systems, air monitoring is most effective when integrated into established surveillance frameworks rather than deployed as a standalone tool.

Unlike airplane wastewater and traveler nasal swab sampling, which are directly linked to arriving international passengers, air sampling in airport terminals lacks a clear demographic or epidemiological boundary. Air collected in congregate terminal spaces reflects a mixed population that can include airport staff, domestic travelers, and members of the surrounding community, introducing uncertainty regarding attribution to inbound international travel. This limitation reduces the specificity of air sampling for monitoring pathogen importation and must be considered when interpreting variant origin or timing signals relative to other aviation-based surveillance modalities. However, air sampling can provide a complementary layer within a multi-modality framework. Its primary value lies in continuous detection of respiratory pathogens within high-risk indoor environments, capturing signals from individuals who may not contribute to wastewater or participate in voluntary nasal sampling. While air monitoring did not demonstrate earlier lineage detection in all aviation wastewater types in this study, it may offer situational awareness, confirmation of ongoing transmission, and persistence signals during outbreak onset or decline, particularly when other data streams are delayed, unavailable, or operationally constrained.

Air monitoring provides a non-invasive means to track pathogen presence and spread in specific environments. It complements clinical surveillance by capturing signals from large numbers of asymptomatic or mildly symptomatic individuals who would otherwise go undetected. By offering insights into pathogen dynamics, air monitoring can support early threat detection and

enable timely public health interventions, even before clinical cases are widely reported. It has been applied in schools[12] and proposed for long-term care facilities and workplace settings. Air monitoring may also be particularly valuable where wastewater surveillance is impractical, such as in maritime environments, where access to wastewater is limited and where dense populations, close contact, and frequent embarkation/disembarkation increase both transmission risk and the potential for pathogen introduction.[23]

In the future, indoor air detection of viral pathogens in airports or other international ports of entry could become a cornerstone of proactive pandemic preparedness. Continuous or intermittent air sampling, coupled with rapid detection technologies, could provide real-time insights into circulating pathogens. Upon detection of elevated viral loads, targeted mitigation measures, such as increased ventilation[24], air purification[25], public health messaging, or resource allocation, could be swiftly launched. This proactive approach, moving beyond reactive clinical case identification, could significantly reduce the risk of disease spread and enhance global health security. Our study highlights air sampling as a feasible, non-invasive strategy for pathogen surveillance. Integrating airport air sampling into existing frameworks can enhance the ability to identify emerging threats and build more resilient, proactive biosecurity systems to address current and future challenges.

Declaration of Competing Interests

DG, BBS, AR, VJM, CWP, XQ, and TWSA were employed by Ginkgo Bioworks at the time of the study and received Ginkgo Bioworks stocks. D.H.O. received support for this project from Inkfish, Heart of Racing, and the University of Wisconsin-Madison Institute for Clinical and Translational Research's Pilot Award program. This work was also supported in part by awards

293 to D.H.O. from the Wisconsin Department of Health Services (435100-A24-ELCProjE) and the
294 US Centers for Disease Control and Prevention (75D30122C15355). D.H.O. and S.L.O. are
295 managing partners of Pathogenuity LLC, a consultancy that advises on environmental
296 monitoring issues. S.L.O.'s work on this project was funded by Inkfish and Heart of Racing.

297 The funders played no role in the drafting of this manuscript. The authors are not aware of any
298 affiliations, memberships, funding, or financial holdings that might be perceived as affecting the
299 objectivity of this manuscript.

300 The findings and conclusions in this report are those of the author(s) and do not necessarily
301 represent the official position of the Centers for Disease Control and Prevention/the Agency for
302 Toxic Substances and Disease Registry.

303 **Author contributions**

304 DG, CRF, SLO, and DHO contributed to ideas, work, writing, accountability and stewardship.
305 CWP contributed to ideas, work, and stewardship. AR and VJM contributed to work, writing and
306 accountability. BBS contributed to writing, accountability, and stewardship. XQ and PBT
307 contributed to work. TWSA contributed to ideas and work. SB and DJ contributed to work. IR
308 contributed to ideas and accountability.

309 **Acknowledgements**

310 We are deeply grateful to our partners at XpresCheck for sample collection and support. We
311 thank Amy Schierhorn for program support. We thank Bo Reese and staff at Center for Genome
312 Innovation, Institute for Systems Genomics, University of Connecticut for sequencing support.
313 We thank the CDC Port Health Station staff including Steve Burchell, Erica Sison, Jonathan

Georges, Helen MacGregor, Kara Adams, and Ayianna Kennerly. We also thank Miranda Stauss and Eli O'Connor in the O'Connor Labs for cartridge tracking.

Data Availability

All raw sequencing data is available in the NCBI sequence read archive (SRA) database under CDC's Traveler-Based Genomic Surveillance Program BioProject PRJNA989177. All other code used to generate figures is available at https://github.com/concentricbyginkgo/TGS-AirMonitoring-Supplemental.

References

1. Tegally, H. *et al.* Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern. *Cell* **186**, 3277-3290.e16 (2023).

2. Baker, R. E. *et al.* Infectious disease in an era of global change. *Nat Rev Microbiol* **20**, 193–205 (2022).

3. Mangili, A. & Gendreau, M. A. Transmission of infectious diseases during commercial air travel. *The Lancet* **365**, 989–996 (2005).

4. Wilder-Smith, A. COVID-19 in comparison with other emerging viral diseases: risk of geographic spread via travel. *Trop Dis Travel Med Vaccines* **7**, 3 (2021).

5. Wegrzyn, R. D. *et al.* Early Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants Using Traveler-based Genomic Surveillance at 4 US Airports, September 2021–January 2022. *Clin Infect Dis* **76**, e540–e543 (2023).

6. Ahmed, W. *et al.* Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater. *Science of The Total Environment* **820**, 153171 (2022).

337 7. Morfino, R. C. Notes from the Field: Aircraft Wastewater Surveillance for Early
338 Detection of SARS-CoV-2 Variants — John F. Kennedy International Airport, New York City,
339 August–September 2022. *MMWR Morb Mortal Wkly Rep* **72**, (2023).

340 8. Agrawal, S. *et al.* Genome Sequencing of Wastewater Confirms the Arrival of the SARS-
341 CoV-2 Omicron Variant at Frankfurt Airport but Limited Spread in the City of Frankfurt,
342 Germany, in November 2021. *Microbiology Resource Announcements* **11**, e01229-21 (2022).

343 9. Bobrovska, S. *et al.* Hospital air sampling enables surveillance of respiratory virus
344 infections and genomes. *Science of The Total Environment* **977**, 179346 (2025).

345 10. Minor, N. R. *et al.* Metagenomic sequencing detects human respiratory and enteric
346 viruses in air samples collected from congregate settings. *Scientific Reports* **13**, 21398 (2023).

347 11. Ramuta, M. D. *et al.* SARS-CoV-2 and other respiratory pathogens are detected in
348 continuous air samples from congregate settings. *Nat Commun* **13**, 4717 (2022).

349 12. Temte, J. *et al.* Four Methods for Monitoring SARS-CoV-2 and Influenza A Virus
350 Activity in Schools. *JAMA Netw Open* **6**, e2346329 (2023).

351 13. Houldcroft, C. J., Beale, M. A. & Breuer, J. Clinical and biological insights from viral
352 genome sequencing. *Nat Rev Microbiol* **15**, 183–192 (2017).

353 14. Hilt, E. E. & Ferrieri, P. Next Generation and Other Sequencing Technologies in
354 Diagnostic Microbiology and Infectious Diseases. *Genes* **13**, 1566 (2022).

355 15. Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and challenges
356 in virus genomic epidemiology. *Trends in Parasitology* **37**, 1038–1049 (2021).

357 16. Quainoo, S. *et al.* Correction for Quainoo et al., "Whole-Genome Sequencing of
358 Bacterial Pathogens: the Future of Nosocomial Outbreak Analysis". *Clinical Microbiology*
359 *Reviews* **31**, 10.1128/cmr.00082-17 (2017).

360 17. Behzad, H., Gojobori, T. & Mineta, K. Challenges and Opportunities of Airborne
361 Metagenomics. *Genome Biology and Evolution* **7**, 1216–1226 (2015).

362 18. Quek, Z. B. R. & Ng, S. H. Hybrid-Capture Target Enrichment in Human Pathogens:
363 Identification, Evolution, Biosurveillance, and Genomic Epidemiology. *Pathogens* **13**, 275
364 (2024).

365 19. Lu, X. *et al.* US CDC Real-Time Reverse Transcription PCR Panel for Detection of
366 Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 8—August 2020 -
367 Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2608.201246.

368 20. Quick, J. nCoV-2019 sequencing protocol. (2020).

369 21. Ma, K. C. *et al.* Genomic Surveillance for SARS-CoV-2 Variants: Circulation of
370 Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024. *MMWR Morb*
371 *Mortal Wkly Rep* **73**, 938–945 (2024).

372 22. Raymenants, J. *et al.* Indoor air surveillance and factors associated with respiratory
373 pathogen detection in community settings in Belgium. *Nat Commun* **14**, 1332 (2023).

374 23. Kumar, P. *et al.* Airborne pathogen monitoring and dispersion modelling on passenger
375 ships: A review. *Science of The Total Environment* **980**, 179571 (2025).

376 24. Faulkner, C. A. *et al.* Comparison of effectiveness and energy use of airborne pathogen
377 mitigation measures to meet clean air targets in a prototypical office building. *Building and*
378 *Environment* **257**, 111466 (2024).

379 25. Azimi, P. & Stephens, B. HVAC filtration for controlling infectious airborne disease
380 transmission in indoor environments: Predicting risk reductions and operational costs. *Build*
381 *Environ* **70**, 150–160 (2013).



Figure 1: PCR detection from airport air samples. Positive qRT-PCR detections and Ct values of Influenza A, SARS-CoV-2, and RNase P controls captured by ambient air monitoring surveillance from congregate areas in 4 U.S. international airports, October 2023–August 2024. The red star indicates a change of assay; quantitative results before and after this point cannot be directly compared. The orange star indicates when a second sampler was added to the San Francisco airport.



Figure 2: Respiratory virus positivity trends for airport air, aviation wastewater, and

traveler nasal swab surveillance. As part of the CDC TGS program, two international airports (SFO and IAD) had overlapping collections for aviation wastewater, airport air, and individual traveler nasal swabs from October 18, 2023-August 27, 2024. Data from these two airports were used to compare virus positivity trends across surveillance modalities. Publicly available data from USA respiratory virus clinical testing (CDC NREVSS) was also included for comparison to national trends. A) Percent positivity for influenza A and SARS-CoV-2 PCR detection compared across surveillance modalities. B-D) Correlation between airport air PCR values for SARS-CoV-2 and (B) aviation wastewater PCR values, (C) traveler nasal percent PCR positivity, and (D) NREVSS clinical percent positivity. Because percent positivity was near 100% for SARS-CoV-2 in airport air and aviation wastewater samples, PCR values (copies/mL wastewater or copies/substrate for air) were analyzed instead of percent positivity. E-G) Correlation between airport air weekly percent positivity for influenza A and (E) aviation wastewater percent positivity, (F) traveler nasal swab percent positivity, and (G) NREVSS clinical percent positivity.



Figure 3a, b: SARS-CoV-2 genomes from wastewater and air samples at two airports (SFO and IAD), samples collected from Jan 29, 2024 to Aug 26, 2024. Genomic sequencing data from **A.** aviation wastewater (SFO-triturator, IAD-airplane) and **B.** Air samples. Aviation wastewater includes both triturator (aggregate airplane lavatory waste) from SFO, and airplane wastewater (individual flight lavatory waste) from IAD.



[redacted]

413

414 **Figure 4: Detection of viral genomes from air samples by metagenomic enrichment**

415 **sequencing**. Nucleic acid extracted from air filters (N=98) collected from three airports (EWR,

416 IAD, SFO) was sequenced using the Illumina Respiratory Viral Oligo hybrid-capture panel for

417 respiratory viruses. Samples to the right of the red line indicate when an RNA concentration step

418 was added to the sequencing library prep protocol. The heatmap shows the normalized

419 abundance of reads mapping to each viral target (RPKM = reads per kilobase per million reads).

420